Missed opportunities: unnecessary medicine use in patients with lung cancer at the end of life - an international cohort study by Todd A et al.
Missed opportunities: unnecessary medicine use in patients with lung cancer at the end 1 
of life: an international cohort study 2 
Adam Todd1* PhD, reader in pharmaceutical public health, adam.todd@newcastle.ac.uk 3 
Jaafar Al-Khafaji2 MD, research associate, jaafar.f.alkhafaji@gmail.com 4 
Nasima Akhter3 PhD, assistant professor (research), nasima.akhter@durham.ac.uk 5 
Adetayo Kasim3 PhD, associate professor (research), a.s.kasim@newcastle.ac.uk 6 
Rachel Quibell4 MBBS, consultant in palliative medicine, rachel.quibell@nuth.nhs.uk 7 
Kelly Merriman5 PhD, administrative director, kmerriman@mdanderson.org 8 
Holly Holmes6 MD, MS, associate professor and division director, 9 
holly.m.holmes@uth.tmc.edu 10 
1. School of Pharmacy, Faculty of Medical Sciences, Newcastle University, UK.  11 
2. Department of Internal Medicine, University of Nevada, Reno School of Medicine, USA. 12 
3. Wolfson Research Institute for Health and Wellbeing, Durham University, UK. 13 
4. Department of Palliative Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, UK. 14 
5. University of Texas MD Anderson Cancer Center, Houston, Texas, USA 15 
6. Division of Geriatric and Palliative Medicine, The University of Texas Health Science Center 16 
at Houston, Texas, USA. 17 
 18 
*Full contact details for corresponding author: adam.todd@newcastle.ac.uk  19 
Room G066,  20 
King George VI Building, 21 
School of Pharmacy 22 
Faculty of Medical Sciences 23 
Newcastle University 24 
Newcastle upon Tyne 25 
NE1 7RU 26 
United Kingdom 27 
Telephone number: +44 (0) 191 208 2355 28 
 29 
Word Count (excluding abstract & tables): 3326. 30 
Running Head: Unnecessary medicine use in patients with lung cancer 31 
Aims 32 
To (1) examine the prescribing of preventative medication in a cohort of people with 33 
advanced lung cancer on hospital admission and discharge across different healthcare 34 
systems; (2) explore the factors that influence preventative medication prescribing at 35 
hospital discharge.   36 
 37 
Methods 38 
A retrospective cohort study across two centers in the United Kingdom and the United 39 
States. The prescribing of preventative medication was examined at hospital admission 40 
and discharge for patients who died of lung cancer; a zero-inflated negative binomial 41 
regression model was used to exam the association between preventative medications 42 
at discharge and patient- and hospital-based factors. Classes of preventative medication 43 
included: vitamins and minerals, anti-diabetic, anti-hypertensive, anti-lipid, and anti-44 
platelet medications. 45 
 46 
Results 47 
In the UK site (n=125 people), the mean number of preventative medications was 1.9 48 
(SD ± 1.7) on admission, and 1.7 (SD ± 1.7) on discharge, whilst in the US site (n=191 49 
people) the mean was 2.6 (SD ± 2.2) on admission and 1.9 (SD ± 2.2) on discharge. 50 
The model found a significant association between the number of preventative drugs 51 
on admission and the number of preventative medications on discharge; the model also 52 
found a significant association between the total number of drugs on discharge and the 53 
number of preventative medications on discharge. Other indicators related to patient 54 
and hospital factors were not significantly associated with preventative medications 55 
supplied on discharge. 56 
 57 
Conclusions  58 
The use of preventative medication was common in lung cancer patients, despite 59 
undergoing discharge. Patient-based and hospital-based factors did not influence the 60 
prescribing of preventative medication. 61 
 62 
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 81 
What is known about this subject? 82 
 The presence of multi-morbid conditions is highly common in a lung cancer 83 
population. 84 
 It is common for this patient group to have complex, costly and often 85 
inappropriate medication regimens. 86 
 This patient group is frequently hospitalized in the last year of life. 87 
 88 
What this study adds? 89 
 The use of preventative medication is common in lung cancer patients is 90 
common, which is evident across different healthcare systems 91 
 There is no association between preventative medication at discharge and 92 
patient-based (e.g stage of cancer), and hospital-based factors (e.g time spent in 93 
hospital). 94 
 Deprescribing interventions directed towards reducing preventative medication 95 
use could be implemented at the point of hospital discharge. 96 
 97 
 98 
 99 
 100 
 101 
 102 
 103 
 104 
 105 
 106 
Background 107 
Lung cancer is the most common cancer in the world with around 1.8 million 108 
new cases diagnosed annually.[1] It is the most frequent cause of cancer-related 109 
mortality, accounting for approximately 1.5 million deaths each year – roughly 110 
equating to around 1 in 5 of all cancer-related deaths.[2] Lung cancer, like the majority 111 
of other cancers, is predominately a disease of older people: around two in three cases 112 
are reported in people aged over 65 years, while the mean age of diagnosis is 70 113 
years.[3]  114 
Due to age as well as common risk factors, the presence of multi-morbid 115 
conditions – including cardiovascular disease, cerebrovascular disease, and 116 
chronic  obstructive pulmonary disease (COPD) – is highly common in a lung cancer 117 
population.[4] The presence of these chronic conditions is accompanied by the chronic 118 
use of medications to maintain disease control or to treat symptoms associated with 119 
these conditions or to prevent further worsening of them. The overall effect of this 120 
paradigm is that polypharmacy is common and the pill burden is high amongst this 121 
patient group.[5-6] This is challenging, particularly for medication used in the context 122 
of primary or secondary prevention: a recent systematic review showed that many 123 
preventative medications are inappropriately prescribed in the context of life limiting 124 
illnesses, such as lung cancer; the review identified vitamins and minerals, anti-125 
diabetic, anti-hypertensive, anti-lipid, and anti-platelet medications, as preventative 126 
medication with questionable benefit.[7] In addition, previous research has also 127 
demonstrated that inappropriate medication use in a palliative setting could increase the 128 
risk of the patient developing severe drug-drug interactions, possibly resulting in 129 
hospitalization or even death.[8] 130 
Previous work has shown that lung cancer patients are frequently hospitalized 131 
in their last year of life – perhaps more so than patients with any other type of cancer.[9] 132 
For example, Mayer and colleagues showed that out of 37,760 cancer-related 133 
Emergency Room (ER) visits, 26.9% were attributable to lung cancer patients 134 
(compared to 6.3%, 6.0%, and 7.7% of visits for breast, prostate, and colorectal patients 135 
respectively).[10] Common reasons for the hospitalization of lung cancer patients 136 
included pain, respiratory distress, and GI issues.[10] Given this observation, and the 137 
fact that lung cancer patients often have complex, costly, and burdensome medication 138 
regimens, it is not clear how episodes of hospitalization – or prolonged periods of time 139 
spent in hospital – influence or change a patient’s medication, or indeed, how this varies 140 
according to healthcare system. In the UK, for example, patients with advanced disease 141 
receiving cancer therapy may be cared for in hospice care for a significant time before 142 
death and may still be admitted to the hospital.[11] In the US, patients are referred to 143 
hospice care late in the disease process, with a median length of stay in hospice of 19 144 
days for patients with cancer.[12] We hypothesized that a hospital stay would present 145 
an opportunity to reduce medications with questionable benefit, and thus, through 146 
medicine optimization and hospital discharge, it would be more likely that preventative 147 
medication would be discontinued. 148 
This work, therefore, aimed to (1) examine the prescribing of preventative 149 
medication in a cohort of people with advanced lung cancer on hospital admission and 150 
discharge across different healthcare systems; and, (2) explore the factors that influence 151 
preventative medication prescribing at hospital discharge. 152 
 (1) describe preventative medication prescribing in a cohort of lung cancer 153 
patients pre- and post- hospital admission across different healthcare systems; and (2) 154 
to explore the factors that influence preventative medication prescribing at hospital 155 
discharge in a cohort of lung cancer patients.   156 
 157 
Methods 158 
Setting 159 
To meet our study aims, two tertiary care centers were chosen as sites of data 160 
collection: MD Anderson Cancer Centre, Houston, Texas, US; and, The Newcastle 161 
Hospitals Foundation Trust, Newcastle-upon-Tyne, UK. MD Anderson solely focuses 162 
on cancer care, and has around 1.5 million patient contacts per year, with patients who 163 
have Medicare, private insurance, or other means of healthcare coverage, whilst The 164 
Newcastle Hospitals provides all aspects of healthcare, including cancer care, and has 165 
around 1.7 million patient contacts per year, the vast majority of which are managed 166 
through the National Health Service (NHS). There are approximately 1800 inpatient 167 
hospital beds across The Newcastle Hospital Foundation Trust and, for MD Anderson, 168 
there are around 600 inpatient beds.[13-14] Study approval and registration was 169 
obtained from each site: as this was a retrospective study on deceased patients, this 170 
work was considered ‘not human subject research’ as defined by the Federal 171 
Regulations. In view of this, full IRB approval was not required, and The Waivers of 172 
Informed Consent and Authorization were granted. 173 
 174 
Design 175 
This was a retrospective cohort study of medication use at hospital admission 176 
and hospital discharge during the hospitalization prior to death for patients who died of 177 
lung cancer. 178 
 179 
Inclusion criteria 180 
Patients were included in the analysis if they had primary non-small cell lung 181 
cancer or small cell lung cancer, were admitted to a hospital study site at least once 182 
within the last 6 months of life, and died in 2013. A hospital admission was defined as 183 
an encounter in which a patient received continuous care at the hospital as an inpatient. 184 
 185 
Exclusion criteria 186 
Any patient who received care exclusively as an outpatient in a study site was 187 
excluded from the study. Patients who died in hospital were excluded. Patients were 188 
excluded if the hospital admission was unrelated to the lung cancer (e.g. road traffic 189 
accident). 190 
 191 
Data sources 192 
Data relating to patient deaths, cancer type and staging were obtained from 193 
either the electronic medical record (MD Anderson) or from cancer registries linked to 194 
the study site (Newcastle). Patient and medication data were then extracted from each 195 
hospital computer system and included the following: medications on admission, 196 
medications on discharge, length of hospital admission, number of hospital admissions 197 
in last 6 months of life, and co-morbidities. Each medication was classified according 198 
to British National Formulary (BNF) category; all continuous and ‘when required’ 199 
medications were included in the analysis. Preventative medication with questionable 200 
benefit was defined in one of five categories: vitamins and minerals, anti-diabetic, anti-201 
hypertensive, anti-lipid, and anti-platelet medications, based on a previous systematic 202 
review.[7] Co-morbidity was calculated according to the Charlson Comorbidity Index, 203 
although for our calculations, we removed the scores related to tumour without 204 
metastases, and metastatic solid tumour for lung cancer, but included other cancers.[15] 205 
 206 
Outcome measures 207 
The primary outcome in this study was the number of preventative medicines 208 
prescribed on hospital discharge. We defined preventative medicines as drugs for 209 
diabetes, hypertension, hyperlipidemia, antiplatelet agents, and vitamins/minerals. We 210 
included clinical and demographic variables, hospitalization variables, and medication 211 
use variables as possible predictors of discharge preventative medicine use.  212 
 213 
Statistical analysis 214 
Patient age, gender, cancer diagnosis, cancer stage, Charlson Comorbidity 215 
Index, hospital length of stay, length from discharge to death, and the number of 216 
preventative medicines used in each category, were stratified by the US and the UK 217 
cohorts. Means, medians, standard deviation, and range for each measure were 218 
reported. The McNemar test was then used to compare preventative medicine use at 219 
admission and at discharge to determine whether there was a significant difference in 220 
the proportion of patients taking any preventative medicine or preventative medicines 221 
in each of the five categories. In multivariable analysis, we conducted the same analyses 222 
for the UK and the US cohorts. With the outcome of number of preventative medicines 223 
on discharge, we constructed zero-inflated negative binomial regression models to 224 
account for excess zeros in the number of preventative drugs at discharge. The decision 225 
to use a zero-inflated negative binomial regression model was made a priori based on 226 
our understanding of the data. We first built models based on groups of variables, 227 
including clinical and demographic variables (age died, gender, cancer type, cancer 228 
stage, comorbidity), hospital variables (length of stay, number of hospitalizations in the 229 
last 6 months of life), and medication use (total preventative medicine use at admission 230 
and preventative medicine use in each of the 5 categories at admission and discharge, 231 
as well as total medicine use at admission and discharge). Except for gender, cancer 232 
type, cancer stage, comorbidity, receipt of types of preventative medicines (yes/no), the 233 
remaining variables were continuous. For the US data only, we included palliative care 234 
consultation as a single, ungrouped variable in the models. We built stepwise models 235 
by adding these groups of variables and did stepwise deletion by groups of variables 236 
and then further by individual variables, retaining variables in the model with p<0.1. 237 
The likelihood ratio test was used to compare models at each step (Appendix 1). The 238 
final US and UK models had some important differences in significant variables, and 239 
we took a final step to investigate whether similar models were appropriate for both 240 
sets of data. A p<0.05 was considered statistically significant. All analyses were 241 
conducted separately for the UK and US cohorts. The UK data were analysed using 242 
SAS version 9.1, and the US data were analysed using STATA version 14. No statistical 243 
comparisons were made between the two cohorts.  244 
 245 
Results 246 
Participant Characteristics  247 
In 2013, a total of 185 lung cancer patients died who received care in the UK 248 
study site, whilst 349 died in the US study site. From the UK data, 19 patients died 6 249 
months after their last hospital admission, 37 patients died in hospital, and 4 patients 250 
had missing data (cancer stage, information relating to medications on admission, and 251 
information relating to medications on discharge). From the US data, 109 patients died 252 
in hospital, 29 were treated only in the ER or on observation status without inpatient 253 
admission, 14 had cancers other than non-small cell or small cell lung cancer, 3 patients 254 
had admissions unrelated to lung cancer, and 3 patients had missing data. In total, there 255 
were 125 patients (UK) and 191 patients (US) included in the analysis.  256 
 257 
Characteristics  258 
The median patient age was 73 years for the UK site (range 48-98 years), and 259 
65 years for the US site (range 22-90 years); there were more males than females for 260 
both study sites, whilst the majority of people presented with stage IV lung cancer; non-261 
small cell cancer lung cancer (NSCLC) was more common than small cell lung cancer 262 
(SCLC).  Of the UK cohort, 62.4% had a Charlson score of 1 or higher, and 52.4% of 263 
the US cohort had a score of 1 or higher (Table 1). 264 
In the last 6 months of life, repeated hospital admissions were common at both 265 
study sites: for the UK site, the mean number was 2.0 (SD ± 1.0), whilst for the US site, 266 
the mean number was 1.9 (SD ± 1.0). The mean length of each hospital admission was 267 
10.9 days (SD ± 9.0) for the UK site, and 7.8 days for the US site (SD ± 7.4), whilst 268 
patients at both sites, on average, lived around 6 weeks after their last hospital 269 
admission. Polypharmacy, defined as 5 ≥ medications, was also common at both sites 270 
(observed in 81.6% and 93.7% of individuals admitted to hospital at UK and US sites, 271 
respectively), with the total number of medications increasing after each hospital 272 
admission (Table 2). 273 
 274 
Preventative medication   275 
The mean number of preventative medications on admission was 1.9 (SD ± 1.7) 276 
and 2.6 (SD ± 2.2) and, for discharge, the mean number was 1.7 (SD ± 1.7) and 1.9 (SD 277 
± 2.2) for UK and US sites, respectively. On admission, approximately 73 per cent of 278 
patients received a preventative medication for the UK site, whilst for the US site 279 
approximately 80 per cent of patients received a preventative medication. Overall, the 280 
number of preventative medications reduced at discharged to 63 per cent for the UK 281 
site, and 69 per cent for the US site; this change was significant for UK and US sites 282 
(Table 3). The most common prescribed preventative medication were the anti-283 
hypertensive agents at the UK site, and vitamin and minerals at the US site; the least 284 
common prescribed medications were the anti-diabetic agents, which was apparent for 285 
both sites. All prescribed preventative medication categories reduced after discharge, 286 
apart from anti-diabetic agents and vitamins and minerals (UK), which increased, 287 
although this was not statistically significant, and anti-hypertensive medication (US), 288 
which remained constant.  289 
 290 
Modeling variables 291 
Overall, the mean number of preventative medications was less on hospital 292 
discharge compared to admission. When we examined how preventative medication at 293 
discharge was related to other factors, the zero-inflated negative binomial regression 294 
model found a significant positive association between the number of preventative 295 
drugs on admission and the number of preventative medications on discharge; for 296 
example, in the UK model, for every 1 preventative drug at admission, the number of 297 
preventative medications at discharge will increase by 1.27, expressed as Incidence 298 
Rate Ratio (IRR) (95% confidence Intervals (CI): 1.17, 1.39); similarly, in the US 299 
model, for every 1 preventative drug at admission, the number of preventative 300 
medications at discharge will increase by 1.13 IRR (95% CI: 1.06, 1.20). There was 301 
also a significant positive association between the total number of drugs on discharge 302 
and the number of preventative medications on discharge, which was evident at both 303 
UK and US study sites (Table 4). In the US model only, there were significant 304 
associations between total drugs on admission with an IRR of 0.95 (95% CI: 0.92, 305 
0.97), having a palliative care consultation with an IRR of 0.73 (95% CI: 0.58, 0.92), 306 
and total medication at discharge with an IRR of 1.10 (95% CI: 1.08, 1.13). None of 307 
the other indicators (age, cancer stage, cancer type, co-morbidity, length of hospital 308 
admission, number of hospitalizations) were significantly associated with preventative 309 
medications on discharge, and their addition/removal did not significantly affect our 310 
models (Appendix 2). 311 
 312 
Discussion 313 
This paper is the first to describe the prescribing of preventative medication in 314 
a cohort of lung cancer patients at hospital admission and discharge  across different 315 
healthcare systems. We have identified a number of key findings that may be of 316 
importance to healthcare practitioners and policy makers: (1) for lung cancer patients 317 
who are admitted to hospital, polypharmacy is common; (2) the mean number of 318 
medications a hospitalized lung cancer patient is prescribed increases after hospital 319 
admission; (3) the prescribing of preventative medications is common amongst 320 
hospitalized lung cancer patients; and, (4) patient factors (such as age, cancer stage, 321 
cancer type, co-morbidity, and number of days between discharge and death) and 322 
hospital factors (such as length of hospital admission, and number of hospitalizations) 323 
were not associated with the prescribing of preventative medication. 324 
While this is the first study to specifically assess prescribing of preventative 325 
medication in lung cancer patients, other studies have explored prescribing and 326 
medicines use for patients who are at end of life. Currow and colleagues, for example, 327 
showed that, in a cohort of palliative care patients, as death approaches, the number of 328 
medications increases from 4.9 to 6.4 – primarily as a result of people using more 329 
symptom specific medications.[16] Of note, the same study also showed the number of 330 
potentially inappropriate medications, as assessed using the Beers criteria, also 331 
increased as death approaches.[16] Other studies have explored the prescribing of 332 
specific classes of medication in the context of limited life expectancy: for example, 333 
Pearson and colleagues showed more than 30 per cent of cancer patients were dispensed 334 
statins within 30 days of death,[17] whilst Bayless and colleagues revealed, in a cohort 335 
of cancer patients, more than 60 per cent of individuals continued with statin therapy 336 
for 2 years after their diagnosis.[18] Our findings lend support to the literature, and 337 
show that lung cancer patients who are admitted to hospital are commonly discharged 338 
with preventative medication; this appears to have been the continuation of current 339 
medication, as opposed to initiating new preventative medication. 340 
In terms of developing an intervention to reduce polypharmacy and rationalize 341 
medications in lung cancer patients – or possibly other life limiting illnesses – this work 342 
is significant. Indeed, our work shows that the point of discharging a patient from 343 
hospital might be an appropriate place to develop an intervention to reduce – or to start 344 
the process of reducing – burdensome preventative medication that is no longer 345 
appropriate given a patient’s reduced life expectancy. Further work should explore the 346 
nature of the intervention, but it is encouraging that, at the US site, a consultation with 347 
a palliative care clinician did appear to be associated with less preventative medication 348 
on discharge. This is consistent with a previous study in the inpatient palliative care 349 
unit at the same US setting that found among 100 consecutive patients admitted to the 350 
unit, medications increased from a mean of 9.2 to 10.1, with an increase in symptomatic 351 
medications and a reduction in medications for comorbid conditions.[19] 352 
Previous literature has also shown that a pharmacist intervention at the point of 353 
discharging has reduced the level of inappropriate prescribing in a general older 354 
population.[20-21] Given the important role of clinical pharmacists in both UK and US 355 
discharge processes, they should play a key role in delivering any intervention aimed 356 
at reducing inappropriate medication in this patient population. It is clear, however, that 357 
any such intervention to reduce inappropriate or burdensome medication should 358 
embrace the principles of deprescribing. Indeed, the term ‘deprescribing’, recently 359 
defined by Reeve and colleagues, as the process of withdrawal of an inappropriate 360 
medication, supervised by a health care professional with the goal of managing 361 
polypharmacy and improving outcome,[22] has received a great deal of recent attention 362 
in the literature. The process of deprescribing has recently been reviewed,[23] and the 363 
literature suggests that in order to achieve a successful outcome many factors need to 364 
be considered, including patient-based (e.g. patient misalignment with goals of 365 
care),[24] and those involving the caregiver.[25] Another issue toward deprescribing is 366 
the lack of robust evidence demonstrating the effectiveness of deprescribing 367 
preventative medication in patients with life limiting illness. Page and colleagues have 368 
shown that deprescribing in older adults appears to be safe and feasible,[26] although, 369 
to date, Kutner and colleagues are the only group to publish a randomised clinical trial 370 
specifically addressing the issue of deprescribing medication in people with life 371 
limiting illness. The trial, which discontinued statin therapy in a cohort of patients with 372 
advanced life limiting illness, showed that stopping statin therapy is safe, and is 373 
associated with reduced costs and improved quality of life.[27] Given the high 374 
prevalence of other preventative medication identified in our cohort of patients, other 375 
trials, exploring the cessation of antihypertensive agents, and anti-diabetic agents 376 
appear to be warranted. A small scale study has, however, shown many palliative care 377 
patients with previously diagnosed hypertension despite having low blood pressure, 378 
and, in some cases, symptoms of postural hypotension, are still using antihypertensive 379 
medication.[28]  380 
While we believe our results are robust, and have important implications for the 381 
way in which medications are prescribed to lung cancer patients, we do acknowledge 382 
our work has several limitations: firstly, we did not assess the appropriateness of 383 
preventative medication, as we just reported on the prescribing. It is possible that some 384 
of the preventative medication was prescribed appropriately (for example, ACE 385 
inhibitors in the case of advanced heart failure); secondly, only including lung cancer 386 
patients who were admitted to hospital, may not give a true account of the medication 387 
histories for all lung cancer patients, given that it is possible that those admitted to 388 
hospital had more complex medication regimens. We do not know if patients were 389 
discharged with a plan for medication reduction after discharge. We also were not able 390 
to collect information on site of discharge or discharge to hospice care, which might be 391 
particularly important in the US cohort. We would, therefore, urge that our results are 392 
interpreted in view of these limitations. In terms of study strengths, we believe that 393 
collecting data across two healthcare systems (the UK, and the US) is a key strength of 394 
the study, and this adds international context to our work. 395 
 396 
Conclusion 397 
Polypharmacy is common in hospitalised lung cancer patients; the use of 398 
preventative medication remained high among such patients, despite undergoing 399 
hospital discharge. Patient-based and hospital-based factors did not influence the 400 
prescribing of preventative medication. There may be scope to develop an intervention 401 
that embraces the principles of deprescribing at the point of hospital discharge to reduce 402 
inappropriate prescribing in lung cancer patients. 403 
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Table 1: Study participant characteristics for UK and US sites 
  UK (%) 
n=125 
US (%) 
n=191 
    
Gender  Female 48.8 46.6 
 Male 51.2 53.4 
 
Cancer type NSCLC 85.6 86.4 
 SCLC 14.4 11.5 
 Other 0.0 2.1 
 
Staging 1A 0.8 2.1 
 1B 3.2 0.0 
 IIA 1.6 0.0 
 IIB 1.6 0.5 
 IIIA 8.8 6.8 
 IIIB 16.0 2.6 
 IV 68.0 88.0 
 
Charlson Cco-morbidity 
Iindex 
0 37.6 47.6 
 1 44.8 23.6 
 2 9.6 17.3 
 3 6.4 6.8 
 4 0.8 2.1 
 5 0.0 1.6 
 6 0.8 0.0 
 7 0.0 0.5 
 8 0.0 0.5 
 
Table 2: Hospital admission and discharge characteristics for study participants 
 
 UK (n=125) US (n=191) 
 
Indicator Mean, SD Median Range 
 
Mean, SD Median Range 
Age (years) 72.8 ± 10.5 73 48-98 63.8 ± 10.9 65 22-90 
 
Length of hospital admission (days) 
 
10.9 ± 9.0 
 
8 
 
1-37 
 
7.8 ± 7.4 
 
6 
 
1-49 
Number of hospital admission within the last 
6 months of life 
2.0 ± 1.0 2 1-5 1.9 ± 1.4 1 1-10 
Number of days discharged before death 
 
43.3 ± 46.0 28 1-178 38.4 ± 40.7 22 1-190 
Total preventative drugs on admission 1.9 ± 1.7 2 0-7 2.6 ± 2.2 2 0-10 
Total preventative drugs at discharge 1.7 ± 1.7 2 0-7 1.9 ± 2.0 1 0-8 
 
Total drugs on admission 
 
8.8 ± 3.8 
 
9 
 
1-18 
 
11.6 ± 5.0 
 
11 
 
0-26 
Total drugs discharge 10.3 ± 4.3 11 1-20 12.1 ± 4.7 12 2-28 
 
 
Table 3: Number of patients with preventive medication at admission and at discharge. 
 UK (n=125)  US (n=191) 
 
 
Preventive Medicine Type N (%) at 
admission 
N (%) at 
discharge 
P-valuea N (%) at 
admission 
N (%) at 
discharge 
 
P-valuea 
Anti-diabetic 8 (6.4) 11 (8.8) 0.375 23 (12.0) 21 (11.0) 0.75 
Anti-hypertensives 59 (47.2) 44 (35.2) 0.001 97 (50.8) 97 (50.8) 1.000 
Anti-lipid 57 (45.6) 40 (32.0) <0.001 61 (31.9) 44 (23.0) 0.032 
Anti-platelet 38 (30.4) 30 (24.0)  0.057 39 (20.4) 33 (17.3) 0.307 
Multivitamins and minerals 30 (24.0) 36 (28.8) 0.286 106 (55.5) 73 (38.2) <0.001 
Any preventive medicine 91 (72.8) 79 (63.2) 0.017 152 (79.6) 132 (69.1) 0.002 
adifference between number at admission and number at discharge, using the McNemar test 
 
Table 4. Zero inflated negative binomial regression models examining association between 
of total preventative drug at discharge with related factors.  
 
 United Kingdom (n=125) 
 
Indicator IRR, 95% CI 
 
0.99 (0.97, 1.01) 
0.95 (0.90, 1.01) 
1.08 (1.03, 1.14) 
1.27 (1.17, 1.39) 
 
Number of days admitted 
Total drugs at admission 
Total drugs at discharge 
Total preventative drugs at admission 
 
 United States (n=191) 
 
Indicator IRR, 95% CI 
 
0.73 (0.58, 0.92) 
0.95 (0.92, 0.97) 
1.33 (1.18, 1.50) 
1.10 (1.08, 1.13) 
1.13 (1.06, 1.20) 
1.25 (1.00, 1.54) 
 
Palliative care consultation 
Total drugs at admission 
Hypertensive drugs at admission 
Total drugs at discharge 
Total preventative drugs at admission 
Anti-platelet drugs at admission 
 
